API CAS 941678-49-5 Ruxolitinib Purity Ruxolitinib Powder Ruxolitinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Ruxolitinib
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Product Name: Ruxolitinib
• Name: Ruxolitinib Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 941678-49-5
• Mf: C17h18n6
• Density: 1.40
• MW: 404.36
• Melting Point: 84-89 C
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 1000kg/Month

Product Description

API CAS 941678-49-5 Ruxolitinib Purity Ruxolitinib Powder Ruxolitinib

Product Description

Product Details

Product Name	Ruxolitinib
Appearance	White Powder
CAS No	941678-49-5
MF	C17H18N6

The phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.

Application&Function

1) Myelofibrosis (a bone marrow disease) that is intermediate or high-risk
2) Primary myelofibrosis.
3) Post-polycythemia vera myelofibrosis.
4) Post-essential thrombocythemia myelofibrosis.
 

Specification